File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: When to consider liver transplantation in hepatocellular carcinoma patients?

TitleWhen to consider liver transplantation in hepatocellular carcinoma patients?
Authors
KeywordsBridging therapy
Down-staging therapy
Extended criteria
Hepatocellular carcinoma
Immunosuppressant
Liver transplantation
Milan Criteria
Salvage transplantation
Issue Date2017
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/hep
Citation
Hepatic Oncology, 2017, v. 4 n. 1, p. 15-24 How to Cite?
AbstractOrthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed.
Persistent Identifierhttp://hdl.handle.net/10722/245319
ISSN
2023 Impact Factor: 1.2
2023 SCImago Journal Rankings: 0.155
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMa, KW-
dc.contributor.authorCheung, TT-
dc.date.accessioned2017-09-18T02:08:31Z-
dc.date.available2017-09-18T02:08:31Z-
dc.date.issued2017-
dc.identifier.citationHepatic Oncology, 2017, v. 4 n. 1, p. 15-24-
dc.identifier.issn2045-0923-
dc.identifier.urihttp://hdl.handle.net/10722/245319-
dc.description.abstractOrthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed.-
dc.languageeng-
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/hep-
dc.relation.ispartofHepatic Oncology-
dc.subjectBridging therapy-
dc.subjectDown-staging therapy-
dc.subjectExtended criteria-
dc.subjectHepatocellular carcinoma-
dc.subjectImmunosuppressant-
dc.subjectLiver transplantation-
dc.subjectMilan Criteria-
dc.subjectSalvage transplantation-
dc.titleWhen to consider liver transplantation in hepatocellular carcinoma patients?-
dc.typeArticle-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.authorityCheung, TT=rp02129-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.2217/hep-2016-0010-
dc.identifier.pmid30191050-
dc.identifier.pmcidPMC6095144-
dc.identifier.hkuros278105-
dc.identifier.volume4-
dc.identifier.issue1-
dc.identifier.spage15-
dc.identifier.epage24-
dc.identifier.isiWOS:000406848900004-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl2045-0923-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats